Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Carcinoma, Basal Cell 4Recurrence 3Basal Cell Nevus Syndrome 3Skin Neoplasms 2Multiple Myeloma 2Medulloblastoma 2Thrombocytosis 1Thrombocythemia, Essential 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Pancreatic Diseases 1Neuroblastoma 1Myeloproliferative Disorders 1Leukemia, Myeloid, Acute 1Leukemia 1Hepatoblastoma 1Hemorrhagic Disorders 1Hematologic Neoplasms 1Hematologic Diseases 1Glioma 1Endometrial Neoplasms 1Colonic Neoplasms 1Carcinoma 1Bone Marrow Diseases 1Blood Platelet Disorders 1Blood Coagulation Disorders 1Astrocytoma 1

Interventions

sonidegib 1ruxolitinib 1Vorinostat 1Bortezomib 111-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Hemorrhagic Disorders × sonidegib × Clear all
NCT01787552 2020-04-15

A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

Novartis

Phase 1/2 Completed
50 enrolled 23 charts
Myeloid

Blood Coagulation Disorders, Blood Platelet Disorders, Bone Marrow Diseases, Hematologic Diseases, Hemorrhagic Disorders, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Thrombocytosis, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡